Get startedLog in
    Picture of Roquefort Therapeutics logo

    ROQ — Roquefort Therapeutics Income Statement

    0.000.00%
    gb flag iconLast trade - 00:00
    FinancialsHighly SpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Roquefort Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

    2021
    December 31st
    Period Length:12 M
    Source:ARS
    Standards:
    IFRS
    Status:Final
    Revenue
    Total Revenue0.001
    Cost of Revenue
    Gross Profit-0.009
    Selling / General / Administrative Expenses
    Research And Development
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses0.918
    Operating Profit-0.917
    Net Income Before Taxes-0.917
    Net Income After Taxes-0.917
    Net Income Before Extraordinary Items
    Net Income-0.917
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-0.917
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.007